|
|
|
|
박찬우 ( Park Chan-Woo ) - 단국대학교 의과대학 제일병원 산부인과
|
|
Abstract
|
|
|
|
|
|
Recent anticancer treatments have led to significant reduction in mortality, but also to an increase in unwanted side effects such as loss of fertility. Combined with an increased age for childbearing, a higher number of cancer survivors require fertility preservation to be pregnant after cancer treatment. The threat of cancer treatment-related infertility can lead to psychological distress, and many patients are interested in maintaining fertility and future pregnancy at the time of cancer diagnosis. International guidelines recommend that physicians discuss, as early as possible, with all patients of reproductive age their risk of infertility from the disease and/or treatment and inform fertility preservation options. Embryo/oocyte cryopreservation are standard strategies for fertility preservation in female patients. Another strategy is pharmacological protection with gonadotropin releasing hormone agonist (GnRH agonist). Ovarian tissue cryopreservation is still considered experimental techniques. In the present manuscript, we summarize and discuss the up-to-date knowledge on fertility preservation in women with cancer patients.
|
|
|
KeyWords
|
|
female, cancer, fertility preservation
|
|
|
원문 및 링크아웃 정보
|
|
|
|
|
등재저널 정보
|
|
|
|
|
|
|